Search Results1-8 of  8

  • OURA Tomonori ID: 9000016402728

    Dragon Genomics Center, Takara Bio Inc. (2009 from CiNii)

    Articles in CiNii:1

    • ARTRA : a new database of the Arabidopsis transcriptome and gene-specific sequences for microarray probes and RNAi triggers (2009)
  • OURA Tomonori ID: 9000018557856

    Department of Biostatistics, Kyoto University School of Public Health (2010 from CiNii)

    Articles in CiNii:1

    • Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling (2010)
  • OURA Tomonori ID: 9000020752437

    Department of Biostatistics, Kyoto University (2010 from CiNii)

    Articles in CiNii:1

    • The discrimination between primary mucinous and metastatic ovarian adenocarcinoma ; (2010)
  • Oura Tomonori ID: 9000312720211

    Eli Lilly Japan K.K., Kobe, 651-0086, Japan (2015 from CiNii)

    Articles in CiNii:1

    • A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial (2015)
  • Oura Tomonori ID: 9000318580680

    Eli Lilly Japan K.K., Kobe, Japan (2016 from CiNii)

    Articles in CiNii:1

    • Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes (2016)
  • Oura Tomonori ID: 9000345378541

    Eli Lilly Japan K.K., Kobe 651-0086, Japan (2017 from CiNii)

    Articles in CiNii:1

    • Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials (2017)
  • Oura Tomonori ID: 9000353364437

    Eli Lilly Japan K.K., Kobe, Japan (2017 from CiNii)

    Articles in CiNii:1

    • Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan (2017)
  • Oura Tomonori ID: 9000378115269

    Eli Lilly Japan K.K., Kobe, Japan (2017 from CiNii)

    Articles in CiNii:1

    • Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes (2017)
Page Top